Last reviewed · How we verify
Lutetium [177Lu] BL-ARC001
Lutetium [177Lu] BL-ARC001 is a Small molecule drug developed by Sichuan Baili Pharmaceutical Co., Ltd.. It is currently in Phase 1 development.
At a glance
| Generic name | Lutetium [177Lu] BL-ARC001 |
|---|---|
| Sponsor | Sichuan Baili Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lutetium [177Lu] BL-ARC001 CI brief — competitive landscape report
- Lutetium [177Lu] BL-ARC001 updates RSS · CI watch RSS
- Sichuan Baili Pharmaceutical Co., Ltd. portfolio CI
Frequently asked questions about Lutetium [177Lu] BL-ARC001
What is Lutetium [177Lu] BL-ARC001?
Lutetium [177Lu] BL-ARC001 is a Small molecule drug developed by Sichuan Baili Pharmaceutical Co., Ltd..
Who makes Lutetium [177Lu] BL-ARC001?
Lutetium [177Lu] BL-ARC001 is developed by Sichuan Baili Pharmaceutical Co., Ltd. (see full Sichuan Baili Pharmaceutical Co., Ltd. pipeline at /company/sichuan-baili-pharmaceutical-co-ltd).
What development phase is Lutetium [177Lu] BL-ARC001 in?
Lutetium [177Lu] BL-ARC001 is in Phase 1.